

Supplementary Box 1
HHS Biodefense MCM requirements:

Anthrax antitoxin
Filovirus vaccine
Anthrax vaccine
Smallpox antiviral
Filovirus antiviral
Junin virus antiviral
Gram(+) broad-spectrum antibiotic
Gram(-) broad-spectrum antibiotic

Note: HHS biodefense drug and vaccine requirements were based on Table 2 of the PHEMCE Implementation Plan. The "filovirus MCM" category was interpreted to include one vaccine and one small molecule drug. Requirements for broad-spectrum antivirals were interpreted to represent three small molecule drugs – one for filoviruses, one for Junin virus, and one for smallpox. (Requirements for filovirus and smallpox antivirals also appear separately in Table 2 – these were only counted once.) Requirements for broad-spectrum antibiotics were interpreted to represent two small molecule drugs with biodefense indications – one for Gram-positive bacteria, and one for Gram-negative bacteria. The requirement for a smallpox vaccine was assumed to have been fulfilled by the

June, 2007 BioShield contract with Bavarian Nordic A/S for the manufacture and delivery of 20 million doses of its MVA-based smallpox vaccine, **IMVAMUNE®**, to the Strategic National Stockpile.